• Synairgen appoints chief regulatory officer in preparation for SNG001 regulatory submissions
  • Demand for healthcare stocks similar to late 90s tech boom, says analyst
  • Synairgen price target maintained at 505p by broker finnCap
  • Synairgen mark ‘incredible year’ working towards COVID-19 treatment
lung x-ray

Quick facts: Synairgen PLC


View company profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

13 Oct 2021

(, ) has appointed Gareth Walters, who brings 30 years’ expertise in global regulatory strategy, to the newly-created role of chief regulatory officer in preparation for regulatory submissions for its SNG001 product.

Chief executive Richard Marsden said: “His experience and expertise in global regulatory strategy will be invaluable as we prepare for SNG001 regulatory submissions.”

Dr Walters previously served as global regulatory affairs head and head of European regulatory affairs for Chugai Pharmaceuticals, where he led strategic and operational regulatory activities in Europe, Japan and the US.

Before this, he held commercial and clinical positions at Roche and various senior regulatory and executive management and board roles at several pharmaceutical and biotech companies, where Synairgen said he played a key role in bringing innovative new medicines to the market, including in the US and Europe.

Read more

30 Sep 2021

Synairgen PLC (AIM:SNG, OTC:SYGGF, FRA:OMY) said the Phase III trial of its SNG001 inhaled, broad-spectrum antiviral is progressing well and it expects to enrol the last patient in November. Top line results are expected in early 2022.

In a statement alongside interim results, Synairgen said its clinical trial team, working alongside clinical research organization Parexel, has gained trial approvals in 17 countries and initiated over 100 trial sites despite the challenges posed by Coronavirus (COVID-19)-related restrictions. SNG001 is designed to treat COVID-19 amongst other conditions.

Read more

24 May 2021

Synairgen PLC (LON:SNG) said lab tests of its inhaled interferon beta, which is being developed to treat people with severe effects of COVID, has shown “potent antiviral activity” against two new variants of the SARS-CoV-2.

The lab tests of SNG001 also demonstrated the “broad-spectrum antiviral activity”, which bodes well for its use across a number of respiratory viruses.

Read more

06 Aug 2020

An upsurge in investor demand for healthcare and biotechnology stocks in the wake of the coronavirus pandemic has been likened to the heady days of the ‘tech boom’ in the late 1990s by one broker.

Andy Thacker at Turner Pope Investments told Proactive that the demand for healthcare stocks among investors was reminiscent of the tech boom in the fact that “investors didn’t want to look at anything else”.

Read more

30 Apr 2021

Synairgen PLC‘s (LON:SNG) latest data from trials of Covid-19 treatment SNG001 has increased the likelihood of a positive read-out from the phase III trial underway currently in hospitalised patients, finnCap said.

The broker added it was sticking with its share price target of 505p and is awaiting the read-out from the phase III trial in the second half of 2021.

Today’s results were from a study of people with SARS-CoV-2 treated at home with SNG001 as well as data from a combined analysis of the hospital and home cohort.

Read more

12 May 2021

Synairgen PLC‘s (LON:SNG) chief executive Richard Marsden speaks to Proactive’s Katie Pilbeam as the firm finds themselves ‘right in the middle of a global emergency’.

Marsden talks about their ‘role’ and their ‘exceptional progress’ for the whole group over 2020 as it continued to develop its treatment for coronavirus (COVID-19) infections.

He hails the speed at which his team has been working, ‘doing five years of work in two’, with the Phase III trial of SNG001 already initiated and the results are expected in the second half of this year after the first patient was dosed in January.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Synairgen CEO Richard Marsden presents six month progress as COVID-19…

Synairgen PLC’s (LON:SNG) chief executive Richard Marsden talks to Proactive London’s Katie Pilbeam about what has been achieved over the past six months.

The Phase III trial of its SNG001 inhaled, broad-spectrum antiviral is progressing well with top line results expected in early…

2 weeks ago

2 min read

Leave A Reply

Please enter your comment!
Please enter your name here